Antitumor Efficacy, Tumor Distribution and Blood Pharmacokinetics of Chitosan/Glyceryl-Monooleate Nanostructures Containing Paclitaxel

• Moore A , MedarovaZ, PotthastandA, DaiG: In vivo targeting of underglycosylated MUC-1 tumor antigen using a multimodal imaging probe.Cancer Res.64, 1821–1827 (2004).
   PubMed Web of Science ®Google Scholar
• Sandri G , BonferoniMC, RossiSet al.: Nanoparticles based on N-trimethylchitosan: evaluation of absorption properties using in vitro (Caco-2 cells) and ex vivo (excised rat jejunum) models.Eur. J. Pharm. Biopharm.65, 68–77 (2007).
   PubMed Web of Science ®Google Scholar
• Bernkop-Schnurch A , WeithalerA, AlbrechtK, GreimelA: Thiomers: preparation and in vitro evaluation of a mucoadhesive nanoparticulate drug delivery system.Int. J. Pharm.317, 76–81 (2006).
   PubMed Web of Science ®Google Scholar
• Cui F , QianandF, YinC: Preparation and characterization of mucoadhesive polymer-coated nanoparticles.Int. J. Pharm.316, 154–161 (2006).
   PubMed Web of Science ®Google Scholar
• Howard KA , RahbekUL, LiuXet al.: RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system.Mol. Ther.14, 476–484 (2006).
   PubMed Web of Science ®Google Scholar
• Zheng F , ShiXW, YangGFet al.: Chitosan nanoparticle as gene therapy vector via gastrointestinal mucosa administration: results of an in vitro and in vivo study.Life Sci.80, 388–396 (2007).
   PubMed Web of Science ®Google Scholar
• Takeuchi H , YamamotoH, NiwaT, HinoT, KawashimaY: Enteral absorption of insulin in rats from mucoadhesive chitosan-coated liposomes.Pharm. Res.13, 896–901 (1996).
   PubMed Web of Science ®Google Scholar
• Takeuchi H , ThongborisuteJ, MatsuiY, SugiharaH, YamamotoH, KawashimaY: Novel mucoadhesion tests for polymers and polymer-coated particles to design optimal mucoadhesive drug delivery systems.Adv. Drug Deliv. Rev.57, 1583–1594 (2005).
   PubMed Web of Science ®Google Scholar
• Thongborisute J , TsurutaA, KawabataY, TakeuchiH: The effect of particle structure of chitosan-coated liposomes and type of chitosan on oral delivery of calcitonin.J. Drug Target.14, 147–154 (2006).
   PubMed Web of Science ®Google Scholar
• Singla AK , GargA, AggarwalD: Paclitaxel and its formulations.Int. J. Pharm.235, 179–192 (2002).
   PubMed Web of Science ®Google Scholar
• Tarr BD , YalkowskySH: A new parenteral vehicle for the administration of some poorly soluble anti-cancer drugs.J. Parenter. Sci. Technol.41, 31–33 (1987).
   PubMedGoogle Scholar
• Chao TC , ChuZ, TsengLMet al.: Paclitaxel in a novel formulation containing less Cremophor EL as first-line therapy for advanced breast cancer: a Phase II trial.Invest. New Drugs.23, 171–177 (2005).
   PubMed Web of Science ®Google Scholar
• Gelderblom H , VerweijJ, NooterK, SparreboomA, CremophorEL: The drawbacks and advantages of vehicle selection for drug formulation.Eur. J. Cancer37, 1590–1598 (2001).
   PubMed Web of Science ®Google Scholar
• Friedl D , GormanG, TreatJ: Hypersensitivity reactions from taxol and etoposide.J. Natl Cancer Inst.85, 2036 (1993).
   PubMedGoogle Scholar
• Rowinsky EK , ChaudhryV, CornblathDR, DonehowerRC: Neurotoxicity of Taxol.J. Natl Cancer Inst. Monogr.15, 107–115 (1993).
   PubMedGoogle Scholar
• Ganguly S , DashAK: A novel in situ gel for sustained drug delivery and targeting.Int. J. Pharm.276, 83–92 (2004).
   PubMed Web of Science ®Google Scholar
• Jauhari S , DashAK: A mucoadhesive in situ gel delivery system for paclitaxel.AAPS PharmSciTech.7, E53 (2006).
   PubMed Web of Science ®Google Scholar
• Trickler WJ , NagvekarAA, DashAK: A novel nanoparticle formulation for sustained paclitaxel delivery.AAPS PharmSciTech.9, 486–493 (2008).
   PubMed Web of Science ®Google Scholar
• Trickler WJ , KhuranaJ, NagvekarAA, DashAK: Chitosan and glyceryl monooleate nanostructures containing gemcitabine: potential delivery system for pancreatic cancer treatment.AAPS PharmSciTech.11, 392–401 (2010).
   PubMed Web of Science ®Google Scholar
• Trickler WJ , NagvekarAA, DashAK: The in vitro sub-cellular localization and in vivo efficacy of novel chitosan/GMO nanostructures containing paclitaxel.Pharm. Res.26, 1963–1973 (2009).
   PubMed Web of Science ®Google Scholar
• O‘Neil P , VitalE, Betancourt-LoriaN, MontesD: Performance evaluation of the complete blood count and white blood cell differential parameters on the AcT 5diff hematology analyzer.Lab. Hematol.7, 116–124 (2001).
   Google Scholar
• Clark G : Staining Procedures (3rd Edition). Williams & Wilkins, MD, USA, 122 (1972).
   Google Scholar
• McKenzie SB : Textbook of Hematology (2nd Edition). Williams & Wilkins, MD, USA, 85–148 (1996).
   Google Scholar
• Lillie RD : Histopathologic Technic and Practical Histochemistry. McGraw-Hill, NY, USA, 149–150 (1965).
   Google Scholar
• Safavy A : Recent developments in taxane drug delivery.Curr. Drug Deliv.5, 42–54 (2008).
   PubMedGoogle Scholar
• Mugabe C , HadaschikBA, KainthanRK, BrooksDE, SoAI, GleaveME: Paclitaxel incorporated in hydrophobically derivatized hyperbranched polyglycerols for intravesical bladder cancer therapy.Br. J. Urol. Int.103, 978–986 (2009).
   Google Scholar
• Zhang Z , LeeSH, GanCW, FengSS: In vitro and in vivo investigation on PLA-TPGS nanoparticles for controlled and sustained small molecule chemotherapy.Pharm. Res.25, 1925–1935 (2008).
   PubMed Web of Science ®Google Scholar
• Nornoo AO , ChowDS: Cremophor-free intravenous microemulsions for paclitaxel II. Stability, in vitro release and pharmacokinetics.Int. J. Pharm.349, 117–123 (2008).
   PubMed Web of Science ®Google Scholar
• Dong Y , FengSS: In vitro and in vivo evaluation of methoxy polyethylene glycol-polylactide (MPEG-PLA) nanoparticles for small-molecule drug chemotherapy.Biomaterials28, 4154–4160 (2007).
   PubMed Web of Science ®Google Scholar
• Lee SW , ChangDH, ShimMS, KimBO, KimSO, SeoMH: Ionically fixed polymeric nanoparticles as a novel drug carrier.Pharm. Res.24, 1508–1516 (2007).
   PubMed Web of Science ®Google Scholar
• Koziara JM , WhismanTR, TsengMT, MumperRJ: In vivo efficacy of novel paclitaxel nanoparticles in paclitaxel-resistant human colorectal tumors.J. Control. Release112, 312–319 (2006).
   PubMed Web of Science ®Google Scholar
• Win KY , FengSS: In vitro and in vivo studies on vitamin E TPGS-emulsified poly(d,l-lactic-co-glycolic acid) nanoparticles for paclitaxel formulation.Biomaterials27, 2285–2291 (2006).
   PubMed Web of Science ®Google Scholar
• Chen DB , YangTZ, LuWL, ZhangQ: In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing paclitaxel.Chem. Pharm. Bull.49, 1444–1447 (2001).
   PubMed Web of Science ®Google Scholar
• Sharma D , ChelviTP, KaurJ, ChakravortyK, DeTK, MaitraA: Novel Taxol formulation: polyvinylpyrrolidone nanoparticle-encapsulated Taxol for drug delivery in cancer therapy.Oncol. Res.8, 281–286 (1996).
   PubMed Web of Science ®Google Scholar
• Wang Y , LiY, ZhangL, FangX: Pharmacokinetics and biodistribution of paclitaxel-loaded Pluronic P105 polymeric micelles.Arch. Pharm. Res.31, 530–538 (2008).
   PubMed Web of Science ®Google Scholar
• Han LM , GuoJ, ZhangLJ, WangQS, FangXL: Pharmacokinetics and biodistribution of polymeric micelles of paclitaxel with Pluronic P123.Acta Pharmacol. Sin.27, 747–753 (2006).
   PubMed Web of Science ®Google Scholar
• Kim SC , KimDW, ShimYHet al.: In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy.J. Control. Release72, 191–202 (2001).
   PubMed Web of Science ®Google Scholar
• Hamaguchi T , MatsumuraY, SuzukiMet al.: NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel.Br. J. Cancer92, 1240–1246 (2005).
   PubMed Web of Science ®Google Scholar
• Zhao Z , HeM, YinLet al.: Biodegradable nanoparticles based on linoleic acid and poly(β-malic acid) double grafted chitosan derivatives as carriers of anticancer drugs.Biomacromolecules10, 565–572 (2009).
   PubMed Web of Science ®Google Scholar
• van Vlerken LE , DuanZ, LittleSR, SeidenMV, AmijiMM: Biodistribution and pharmacokinetic analysis of paclitaxel and ceramide administered in multifunctional polymer-blend nanoparticles in drug resistant breast cancer model.Mol. Pharm.5, 516–526 (2008).
   PubMed Web of Science ®Google Scholar
• Jennens R , RischinD, YuenK, TonerG, MillwardM: Comparison of neutropenia in a randomized, crossover trial of 3-, 6-, and 24-h infusions of paclitaxel.Gynecol. Oncol.91, 190–193 (2003).
   PubMed Web of Science ®Google Scholar
• Gianni L , MunzoneE, CapriGet al.: Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines.J. Natl Cancer Inst.87, 1169–1175 (1995).
   PubMed Web of Science ®Google Scholar

Patent

• Dash A, Trickler W: Mucoadhesive nanoparticles for cancer treatment. Patent application number: 20090275526 (Filed on 26 October 2007).
   Google Scholar

Website

• Trade Mark on Nanome, assigned to Creighton University on May 28, 2008 www.trademarks411.com/marks/77485378-nanome
   Google Scholar